Cargando…

Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma

Cisplatin is one of the most effective chemotherapeutic agents commonly used for several malignancies including oral squamous cell carcinoma (OSCC). Although cisplatin resistance is a major obstacle to effective treatment and is associated with poor prognosis of OSCC patients, the molecular mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales: Suenaga, Naoki, Kuramitsu, Mimi, Komure, Kanae, Kanemaru, Ayumi, Takano, Kanako, Ozeki, Kazuya, Nishimura, Yuka, Yoshida, Ryoji, Nakayama, Hideki, Shinriki, Satoru, Saito, Hideyuki, Jono, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829433/
https://www.ncbi.nlm.nih.gov/pubmed/31635163
http://dx.doi.org/10.3390/ijms20205194
_version_ 1783465555094667264
author Suenaga, Naoki
Kuramitsu, Mimi
Komure, Kanae
Kanemaru, Ayumi
Takano, Kanako
Ozeki, Kazuya
Nishimura, Yuka
Yoshida, Ryoji
Nakayama, Hideki
Shinriki, Satoru
Saito, Hideyuki
Jono, Hirofumi
author_facet Suenaga, Naoki
Kuramitsu, Mimi
Komure, Kanae
Kanemaru, Ayumi
Takano, Kanako
Ozeki, Kazuya
Nishimura, Yuka
Yoshida, Ryoji
Nakayama, Hideki
Shinriki, Satoru
Saito, Hideyuki
Jono, Hirofumi
author_sort Suenaga, Naoki
collection PubMed
description Cisplatin is one of the most effective chemotherapeutic agents commonly used for several malignancies including oral squamous cell carcinoma (OSCC). Although cisplatin resistance is a major obstacle to effective treatment and is associated with poor prognosis of OSCC patients, the molecular mechanisms by which it develops are largely unknown. Cylindromatosis (CYLD), a deubiquitinating enzyme, acts as a tumor suppressor in several malignancies. Our previous studies have shown that loss of CYLD expression in OSCC tissues is significantly associated with poor prognosis of OSCC patients. Here, we focused on CYLD expression in OSCC cells and determined whether loss of CYLD expression is involved in cisplatin resistance in OSCC and elucidated its molecular mechanism. In this study, to assess the effect of CYLD down-regulation on cisplatin resistance in human OSCC cell lines (SAS), we knocked-down the CYLD expression by using CYLD-specific siRNA. In cisplatin treatment, cell survival rates in CYLD knockdown SAS cells were significantly increased, indicating that CYLD down-regulation caused cisplatin resistance to SAS cells. Our results suggested that cisplatin resistance caused by CYLD down-regulation was associated with the mechanism through which both the reduction of intracellular cisplatin accumulation and the suppression of cisplatin-induced apoptosis via the NF-κB hyperactivation. Moreover, the combination of cisplatin and bortezomib treatment exhibited significant anti-tumor effects on cisplatin resistance caused by CYLD down-regulation in SAS cells. These findings suggest the possibility that loss of CYLD expression may cause cisplatin resistance in OSCC patients through NF-κB hyperactivation and may be associated with poor prognosis in OSCC patients.
format Online
Article
Text
id pubmed-6829433
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68294332019-11-18 Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma Suenaga, Naoki Kuramitsu, Mimi Komure, Kanae Kanemaru, Ayumi Takano, Kanako Ozeki, Kazuya Nishimura, Yuka Yoshida, Ryoji Nakayama, Hideki Shinriki, Satoru Saito, Hideyuki Jono, Hirofumi Int J Mol Sci Article Cisplatin is one of the most effective chemotherapeutic agents commonly used for several malignancies including oral squamous cell carcinoma (OSCC). Although cisplatin resistance is a major obstacle to effective treatment and is associated with poor prognosis of OSCC patients, the molecular mechanisms by which it develops are largely unknown. Cylindromatosis (CYLD), a deubiquitinating enzyme, acts as a tumor suppressor in several malignancies. Our previous studies have shown that loss of CYLD expression in OSCC tissues is significantly associated with poor prognosis of OSCC patients. Here, we focused on CYLD expression in OSCC cells and determined whether loss of CYLD expression is involved in cisplatin resistance in OSCC and elucidated its molecular mechanism. In this study, to assess the effect of CYLD down-regulation on cisplatin resistance in human OSCC cell lines (SAS), we knocked-down the CYLD expression by using CYLD-specific siRNA. In cisplatin treatment, cell survival rates in CYLD knockdown SAS cells were significantly increased, indicating that CYLD down-regulation caused cisplatin resistance to SAS cells. Our results suggested that cisplatin resistance caused by CYLD down-regulation was associated with the mechanism through which both the reduction of intracellular cisplatin accumulation and the suppression of cisplatin-induced apoptosis via the NF-κB hyperactivation. Moreover, the combination of cisplatin and bortezomib treatment exhibited significant anti-tumor effects on cisplatin resistance caused by CYLD down-regulation in SAS cells. These findings suggest the possibility that loss of CYLD expression may cause cisplatin resistance in OSCC patients through NF-κB hyperactivation and may be associated with poor prognosis in OSCC patients. MDPI 2019-10-20 /pmc/articles/PMC6829433/ /pubmed/31635163 http://dx.doi.org/10.3390/ijms20205194 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Suenaga, Naoki
Kuramitsu, Mimi
Komure, Kanae
Kanemaru, Ayumi
Takano, Kanako
Ozeki, Kazuya
Nishimura, Yuka
Yoshida, Ryoji
Nakayama, Hideki
Shinriki, Satoru
Saito, Hideyuki
Jono, Hirofumi
Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma
title Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma
title_full Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma
title_fullStr Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma
title_full_unstemmed Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma
title_short Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma
title_sort loss of tumor suppressor cyld expression triggers cisplatin resistance in oral squamous cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829433/
https://www.ncbi.nlm.nih.gov/pubmed/31635163
http://dx.doi.org/10.3390/ijms20205194
work_keys_str_mv AT suenaganaoki lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma
AT kuramitsumimi lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma
AT komurekanae lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma
AT kanemaruayumi lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma
AT takanokanako lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma
AT ozekikazuya lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma
AT nishimurayuka lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma
AT yoshidaryoji lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma
AT nakayamahideki lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma
AT shinrikisatoru lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma
AT saitohideyuki lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma
AT jonohirofumi lossoftumorsuppressorcyldexpressiontriggerscisplatinresistanceinoralsquamouscellcarcinoma